FIELD: medicine.
SUBSTANCE: invention relates to medicine, and deals with transcutaneous medication for treatment of Parkinson disease, which contains combination of at least two active substances.
EFFECT: invention ensures supradditive addition of substances effect, harmonised and mutually adapted levels of concentration of separate components of active substances, increased safety of combined therapy.
11 cl
| Title | Year | Author | Number |
|---|---|---|---|
| NEW USING (R)-(-)-2-[5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL]-CHROMAN AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS | 2001 |
|
RU2278663C2 |
| NEW APPLICATIONS | 2019 |
|
RU2836384C2 |
| NOVEL USING 2-[5-(4-FLUOROPHENYL)-3-PYRIDYLMETHYLAMINOMETHYL]-CHROMAN AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS | 2002 |
|
RU2297833C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2540470C9 |
| METHODS OF PRODUCING A STABLE LIQUID DRUGS AND COMPOSITIONS THEREOF | 2010 |
|
RU2589697C2 |
| METHODS OF PARKINSON'S DISEASE TREATMENT | 2004 |
|
RU2342929C2 |
| SELECTIVE INVERSE SEROTONIN 2A/2C RECEPTOR AGONISTS APPLICABLES AS THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISORDERS | 2008 |
|
RU2465267C2 |
| AGENT FOR TREATMENT AND PREVENTION OF PARKINSON'S DISEASE | 2006 |
|
RU2324492C1 |
| SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS, USED AS THERAPEUTICS FOR NEURODEGENERATIVES DISEASES | 2004 |
|
RU2332401C2 |
| AGENT FOR PARKINSON DISEASE TREATMENT CONTAINING COMPOUND IMPROVING ASTROCYTE FUNCTION AS ACTIVE INGREDIENT | 2001 |
|
RU2275906C2 |
